lymphoma

Gilead’s Yescarta extends survival in lymphoma study
Gilead’s Yescarta extends survival in lymphoma study
BioPharma Dive
Gilead Sciences
Yescarta
CAR-T
lymphoma
large B-cell lymphoma
Flag link:
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
Fierce Biotech
Gossamer Bio
clinical trials
GB5121
lymphoma
Flag link:
Pfizer to buy Seagen in $43B cancer drug deal
Pfizer to buy Seagen in $43B cancer drug deal
BioPharma Dive
Pfizer
Seagen
M&A
lymphoma
Adcetris
Flag link:
Cancer drug startup Cargo raises $200M to solve CAR-T relapse
Cancer drug startup Cargo raises $200M to solve CAR-T relapse
BioPharma Dive
Cargo Therapeutics
lymphoma
CAR-T
Flag link:
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
Endpoints
FDA
priority review
Pfizer
Prevnar 20
vaccines
Roche
bispecific antibodies
glofitamab
lymphoma
Flag link:
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
BioPharma Dive
FDA
drug approvals
HIV
lymphoma
multiple sclerosis
Gilead Sciences
Roche
TG Therapeutics
Flag link:
Roche takes over development of Biogen-partnered lymphoma drug
Roche takes over development of Biogen-partnered lymphoma drug
BioPharma Dive
Roche
Biogen
lymphoma
glofitamab
Flag link:
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
Fierce Pharma
Roche
ASH 2022
AbbVie
Regeneron
lymphoma
Lunsumio
glofitamab
Flag link:
With 70% staff gone, Nordic Nanovector board members jump ship amid 'strategic review'
With 70% staff gone, Nordic Nanovector board members jump ship amid 'strategic review'
Fierce Biotech
Nordic Nanovector
Norway
lymphoma
layoffs
Flag link:
FDA lifts partial hold on Curis' lymphoma study — shares spike
FDA lifts partial hold on Curis' lymphoma study — shares spike
Endpoints
FDA
Curis
lymphoma
clinical trials
emavusertib
Flag link:
Legend scraps early-stage CAR-T for lymphoma 6 weeks after clinical hold lifted
Legend scraps early-stage CAR-T for lymphoma 6 weeks after clinical hold lifted
Fierce Biotech
Legend Biotech
CAR-T
cell therapy
clinical trials
lymphoma
LB1901
Flag link:
Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients
Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients
BioSpace
ASCO 2022
JNJ
Janssen
Imbruvica
clinical trials
lymphoma
Flag link:
ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug
ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug
Fierce Pharma
ASCO 2022
Seagen
Takeda
Adcetris
lymphoma
Flag link:
Roche trumpets new glofitamab data in lymphoma at ASCO
Roche trumpets new glofitamab data in lymphoma at ASCO
Pharmaforum
Roche
ASCO 2022
glofitamab
lymphoma
bispecific antibodies
Flag link:
CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise
CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise
BioSpace
CRISPR Therapeutics
CTX130
clinical trials
lymphoma
EHA
Flag link:
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Pharmaforum
Gilead Sciences
Kite Pharma
CAR-T
Bristol Myers Squibb
lymphoma
large B-cell lymphoma
Flag link:
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
Fierce Pharma
Bristol Myers Squibb
legal
Breyanzi
shareholders
CAR-T
liso-cel
lymphoma
Flag link:
Biogen buys into fast-advancing Roche cancer drug
Biogen buys into fast-advancing Roche cancer drug
BioPharma Dive
Biogen
Roche
lymphoma
cancer
Flag link:
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
Fierce Pharma
Gilead Sciences
Yescarta
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Flag link:
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
Flag link:

Pages